MetaCap

Fulcrum Therapeutics (FULC) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fulcrum Therapeutics is the larger company by market cap ($281.8 million vs $264.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FULC-0.81%VCRE-42.12%
+8%-21%-49%
Jul 6, 20261 yearNov 20, 2026
FULC+5.43%VCRE-31.75%
+13%-12%-37%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FULC versus VCRE key metrics
MetricFULCVCRE
Share price$3.69$9.41
Market cap$281.85M$264.89M
1-day change-0.54%-5.09%
YTD return-67.37%—
1-year return-67.32%—
5-year return-75.50%—
EPS (TTM)$-1.04$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-74.88M—
52-week high$15.74$17.80
52-week low$2.83$7.88
Distance from 52-week high-76.56%-47.16%
Analyst consensusholdstrong_buy
Avg. price target upside-0.54%+158.90%
Average volume1.37M23.31K
Shares outstanding76.38M28.16M
Employees5550
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Fulcrum Therapeutics

FULC stock →

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

FULC vs VCRE FAQ

Which is bigger, Fulcrum Therapeutics or Vicore Pharma AB?

Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $281.85M compared with $264.89M for Vicore Pharma AB (VCRE).

Are Fulcrum Therapeutics and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons